Based on preclinical studies, other strategies to augment EGFR inhibition includes use of bortezomib in combination with EGFR kinase inhibitors due to its growth inhibitory and pro-apoptic effects on cancer cell lines[12] and dasatinib in combination with EGFR kinase inhibitor as in vitro data from NSCLC cell lines demonstrates that Src inhibition may enhance the antitumor activity of EGFR inhibition in the presence of EGFR mutations[11]. Here, SRC is linked to non-small cell lung carcinoma.